Enanta Pharmaceuticals (ENTA) Equity Ratio (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Equity Ratio data on file, last reported at 0.37 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 27.92% year-over-year to 0.37; the trailing twelve-month figure through Mar 2026 stood at 0.37 (up 27.92% YoY), and the FY2025 full-year result was 0.23, down 32.59% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.37, down from 0.38 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.88 in Q1 2022 and bottomed at 0.23 in Q3 2025.
• The 5-year median for Equity Ratio is 0.4 (2024), against an average of 0.51.
• The widest annual swing landed in 2024, when Equity Ratio plunged 51.32%; it then increased 27.92% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.87 in 2022, then sank by 48.27% to 0.45 in 2023, then decreased by 28.38% to 0.32 in 2024, then climbed by 19.79% to 0.38 in 2025, then slipped by 3.57% to 0.37 in 2026.
• The last three Equity Ratio figures came in at 0.37 (Q1 2026), 0.38 (Q4 2025), and 0.23 (Q3 2025), per Business Quant data.

Peer Comparison